Brinda Manchireddy, MD
Endocrinology, Diabetes & Metabolism · Fredricksburg, VANPI 1447606488
Payments from drug & device makers
Across 164 payments — averaging $23.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$481
- Lilly USA, LLC$471
- Amgen$335
- Abbott$238
- Sanofi-aventis U.S. LLC$220
- Sequel Med Tech, LLC$189
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,82799%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $481 |
| Lilly USA, LLC | 23 | $471 |
| Amgen(2 entities) | 10 | $335 |
| Abbott | 17 | $238 |
| Sanofi-aventis U.S. LLC | 8 | $220 |
| Sequel Med Tech, LLC | 4 | $189 |
| Boehringer Ingelheim | 7 | $177 |
| Madrigal Pharmaceuticals | 3 | $177 |
| Xeris Pharmaceuticals, Inc. | 8 | $172 |
| IBSA Pharma Inc. | 7 | $164 |
| Antares Pharma, Inc. | 5 | $127 |
| Insulet Corporation | 5 | $119 |
| Medtronic | 6 | $112 |
| Dexcom, Inc. | 3 | $83 |
| Bayer | 4 | $76 |
| Neurocrine Biosciences, Inc. | 3 | $72 |
| AstraZeneca | 3 | $64 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Radius Health, Inc. | 2 | $49 |
| Lifescan, Inc. | 2 | $48 |
| Corcept Therapeutics | 2 | $41 |
| Ascendis Pharma Endocrinology Inc | 2 | $40 |
| Amphastar Pharmaceuticals, Inc. | 2 | $37 |
| Averitas Pharma Inc. | 2 | $37 |
| Tolmar, Inc. | 2 | $37 |
| AbbVie | 2 | $29 |
| Cequr Corporation | 2 | $26 |
| Astellas Pharma US Inc | 1 | $26 |
| Tandem Diabetes Care, Inc. | 1 | $25 |
| BETA Bionics, Inc. | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Pfizer | 1 | $18 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,851 in reported general payments places this provider in the 65th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 116 | $248,579 |
| OzempicSemaglutide | 108 | $209,480 |
| MounjaroTirzepatide | 106 | $209,096 |
| JardianceEmpagliflozin | 83 | $111,501 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 54 | $50,803 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $41,784 |
| FarxigaDapagliflozin Propanediol | 35 | $40,167 |
| JanuviaSitagliptin Phosphate | 22 | $26,882 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $24,835 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 171 | $24,829 |
| Humalog Kwikpen U-100Insulin Lispro | 53 | $18,596 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 41 | $17,094 |
| Novolog FlexpenInsulin Aspart | 59 | $16,157 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 131 | $14,773 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,782 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Baqsimi | $471 | $465,494253 claims |
| Novo NordiskOzempic | $481 | $209,480108 claims |
| Boehringer IngelheimJardiance, Tradjenta | $177 | $118,10496 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $220 | $50,80354 claims |
| AstraZenecaFarxiga | $64 | $40,16735 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $3,902299 claims |
| AbbVieSynthroid | $29 | $2,26135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Fredricksburg
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
- Dewey BaileyRoanoke$645K
- James la RocqueChesapeake$576K
- Samamtha HudsonMidlothian$372K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.